Precision Biologics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
11
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 30, 2026The maintenance fee for Colon and Pancreas Cancer Peptidomimetics (US 9,068,014) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
- 1 fee due Mar 26, 2027The maintenance fee for Monoclonal antibody neo-201 for the treatment of human carcinomas (US 11,767,367) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Apr 27, 2027The maintenance fee for Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers (US 9,169,326) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for Colon and Pancreas Cancer Peptidomimetics (US 10,533,040) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers (US 11,952,429) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,535,667 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 12,460,013 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 11,572,413 | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers In force · From the USPTO record | In force | From the USPTO record | |
| US 7,829,678 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · High confidence | In force | High confidence | |
| US 9,371,375 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · Medium confidence | In force | Medium confidence | |
| US 10,023,650 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · Low confidence | In force | Low confidence | |
| US 11,952,429 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · High confidence | In force | High confidence | |
| US 12,344,676 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · Low confidence | In force | Low confidence | |
| US 8,524,456 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · High confidence | In force | High confidence | |
| US 8,802,090 | Recombinant Monoclonal Antibodies and Corresponding Antigens for Colon and Pancreatic Cancers In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 2 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 3 abandoned · 4 no status recorded